Product Name: LDK-378
LDK-378 Chemical Structure
5 stars, based on 86 reviews
In stock! Order now!
Price of LDK-378
We offer a substantial discount on larger orders,
please inquire via firstname.lastname@example.org
or Fax: 1-201-884-1288 (USA Fax#)
LDK-378 is the second generation of ALK inhibitor which shows substantial clinical activity in patients with ALK-positive non-small cell lung cancer (NSCLC), with an overall response rate of 81% in patients previously treated with the US FDA approved ALK inhibitor crizotinib (PF-02341066).
LDK-378 targets ALK, a key gene implicated in the development of some lung cancers, lymphomas, and childhood neuroblastomas. Approximately 6-8% of all NSCLCs are ALK-positive; these cancers are more likely to affect nonsmokers and younger individuals. LDK378 is a selective ALK inhibitor that has demonstrated enhanced potency over crizotinib and noteworthy antitumor activity in preclinical models, including in crizotinib-resistant tumors.
Mol. Formula: C28H36ClN5O3S
Storage Conditions: 2ºC to 8 ºC, or -20ºC for 3 years.
Purchase(buy) CDK inhibitor LDK-378 at Active Biochem
and the United State(U.S.), Germany, Japan, France,United Kingdom(UK),Switzerland, Australia distributors.